Logo image of ZYXI

ZYNEX INC (ZYXI) Stock Fundamental Analysis

NASDAQ:ZYXI - Nasdaq - US98986M1036 - Common Stock - Currency: USD

7.19  -0.22 (-2.97%)

After market: 7.19 0 (0%)

Fundamental Rating

7

ZYXI gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 190 industry peers in the Health Care Equipment & Supplies industry. ZYXI gets an excellent profitability rating and is at the same time showing great financial health properties. ZYXI is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one! These ratings would make ZYXI suitable for growth and quality investing!


Dividend Valuation Growth Profitability Health

Quickly go to:

8

1. Profitability

1.1 Basic Checks

ZYXI had positive earnings in the past year.
ZYXI had a positive operating cash flow in the past year.
Each year in the past 5 years ZYXI has been profitable.
Each year in the past 5 years ZYXI had a positive operating cash flow.
ZYXI Yearly Net Income VS EBIT VS OCF VS FCFZYXI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 5M 10M 15M 20M

1.2 Ratios

ZYXI has a better Return On Assets (3.83%) than 78.72% of its industry peers.
ZYXI has a Return On Equity of 13.49%. This is amongst the best in the industry. ZYXI outperforms 87.77% of its industry peers.
The Return On Invested Capital of ZYXI (6.42%) is better than 82.45% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for ZYXI is significantly above the industry average of 8.19%.
The 3 year average ROIC (13.70%) for ZYXI is well above the current ROIC(6.42%). The reason for the recent decline needs to be investigated.
Industry RankSector Rank
ROA 3.83%
ROE 13.49%
ROIC 6.42%
ROA(3y)11.51%
ROA(5y)16.14%
ROE(3y)23.28%
ROE(5y)26.81%
ROIC(3y)13.7%
ROIC(5y)18.17%
ZYXI Yearly ROA, ROE, ROICZYXI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -200 -400 -600 -800

1.3 Margins

ZYXI's Profit Margin of 2.49% is fine compared to the rest of the industry. ZYXI outperforms 73.40% of its industry peers.
ZYXI's Profit Margin has declined in the last couple of years.
ZYXI's Operating Margin of 4.57% is fine compared to the rest of the industry. ZYXI outperforms 71.81% of its industry peers.
In the last couple of years the Operating Margin of ZYXI has declined.
With an excellent Gross Margin value of 80.20%, ZYXI belongs to the best of the industry, outperforming 92.55% of the companies in the same industry.
ZYXI's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 4.57%
PM (TTM) 2.49%
GM 80.2%
OM growth 3Y-23.1%
OM growth 5Y-29.08%
PM growth 3Y-22.54%
PM growth 5Y-29.4%
GM growth 3Y0.1%
GM growth 5Y-0.45%
ZYXI Yearly Profit, Operating, Gross MarginsZYXI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20 -20 40 60 80

More info and screens

7

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), ZYXI is creating some value.
The number of shares outstanding for ZYXI has been reduced compared to 1 year ago.
The number of shares outstanding for ZYXI has been reduced compared to 5 years ago.
ZYXI has a worse debt/assets ratio than last year.
ZYXI Yearly Shares OutstandingZYXI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M
ZYXI Yearly Total Debt VS Total AssetsZYXI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

2.2 Solvency

ZYXI has an Altman-Z score of 4.18. This indicates that ZYXI is financially healthy and has little risk of bankruptcy at the moment.
With a decent Altman-Z score value of 4.18, ZYXI is doing good in the industry, outperforming 73.94% of the companies in the same industry.
The Debt to FCF ratio of ZYXI is 3.83, which is a good value as it means it would take ZYXI, 3.83 years of fcf income to pay off all of its debts.
ZYXI's Debt to FCF ratio of 3.83 is amongst the best of the industry. ZYXI outperforms 85.64% of its industry peers.
ZYXI has a Debt/Equity ratio of 1.66. This is a high value indicating a heavy dependency on external financing.
ZYXI has a worse Debt to Equity ratio (1.66) than 83.51% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.66
Debt/FCF 3.83
Altman-Z 4.18
ROIC/WACC0.77
WACC8.35%
ZYXI Yearly LT Debt VS Equity VS FCFZYXI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M 40M 60M

2.3 Liquidity

A Current Ratio of 3.94 indicates that ZYXI has no problem at all paying its short term obligations.
ZYXI's Current ratio of 3.94 is fine compared to the rest of the industry. ZYXI outperforms 69.68% of its industry peers.
ZYXI has a Quick Ratio of 3.15. This indicates that ZYXI is financially healthy and has no problem in meeting its short term obligations.
ZYXI has a better Quick ratio (3.15) than 67.55% of its industry peers.
Industry RankSector Rank
Current Ratio 3.94
Quick Ratio 3.15
ZYXI Yearly Current Assets VS Current LiabilitesZYXI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M

More info and screens

7

3. Growth

3.1 Past

ZYXI shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -25.58%.
Measured over the past years, ZYXI shows a quite strong growth in Earnings Per Share. The EPS has been growing by 10.79% on average per year.
ZYXI shows a small growth in Revenue. In the last year, the Revenue has grown by 4.21%.
The Revenue has been growing by 42.02% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-25.58%
EPS 3Y21.48%
EPS 5Y10.79%
EPS Q2Q%-30%
Revenue 1Y (TTM)4.21%
Revenue growth 3Y32.02%
Revenue growth 5Y42.02%
Sales Q2Q%0.1%

3.2 Future

The Earnings Per Share is expected to grow by 30.78% on average over the next years. This is a very strong growth
Based on estimates for the next years, ZYXI will show a quite strong growth in Revenue. The Revenue will grow by 16.39% on average per year.
EPS Next Y-53.64%
EPS Next 2Y5.12%
EPS Next 3Y26.34%
EPS Next 5Y30.78%
Revenue Next Year4.43%
Revenue Next 2Y11.84%
Revenue Next 3Y14.78%
Revenue Next 5Y16.39%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
ZYXI Yearly Revenue VS EstimatesZYXI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M 400M 500M
ZYXI Yearly EPS VS EstimatesZYXI Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0.5 1 1.5 2 2.5

More info and screens

6

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 22.47 indicates a rather expensive valuation of ZYXI.
ZYXI's Price/Earnings ratio is rather cheap when compared to the industry. ZYXI is cheaper than 83.51% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 29.63. ZYXI is valued slightly cheaper when compared to this.
The Price/Forward Earnings ratio is 14.79, which indicates a correct valuation of ZYXI.
Based on the Price/Forward Earnings ratio, ZYXI is valued cheaply inside the industry as 88.83% of the companies are valued more expensively.
The average S&P500 Price/Forward Earnings ratio is at 22.68. ZYXI is valued slightly cheaper when compared to this.
Industry RankSector Rank
PE 22.47
Fwd PE 14.79
ZYXI Price Earnings VS Forward Price EarningsZYXI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, ZYXI is valued a bit cheaper than 78.72% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, ZYXI is valued cheaply inside the industry as 92.02% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 14.75
EV/EBITDA 18.75
ZYXI Per share dataZYXI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6

4.3 Compensation for Growth

ZYXI has an outstanding profitability rating, which may justify a higher PE ratio.
ZYXI's earnings are expected to grow with 26.34% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)2.08
EPS Next 2Y5.12%
EPS Next 3Y26.34%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ZYXI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ZYNEX INC

NASDAQ:ZYXI (2/21/2025, 8:00:02 PM)

After market: 7.19 0 (0%)

7.19

-0.22 (-2.97%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)10-24 2024-10-24/amc
Earnings (Next)02-27 2025-02-27/amc
Inst Owners26.51%
Inst Owner Change-96.91%
Ins Owners51.18%
Ins Owner Change-0.16%
Market Cap229.00M
Analysts84.44
Price Target17.85 (148.26%)
Short Float %29.19%
Short Ratio63.87
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0.25%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-13.88%
Min EPS beat(2)-48.85%
Max EPS beat(2)21.1%
EPS beat(4)2
Avg EPS beat(4)-26.66%
Min EPS beat(4)-100%
Max EPS beat(4)21.11%
EPS beat(8)6
Avg EPS beat(8)24.07%
EPS beat(12)9
Avg EPS beat(12)15.22%
EPS beat(16)12
Avg EPS beat(16)14.96%
Revenue beat(2)0
Avg Revenue beat(2)-4.87%
Min Revenue beat(2)-6.12%
Max Revenue beat(2)-3.62%
Revenue beat(4)0
Avg Revenue beat(4)-7.27%
Min Revenue beat(4)-14.98%
Max Revenue beat(4)-3.62%
Revenue beat(8)1
Avg Revenue beat(8)-3.96%
Revenue beat(12)1
Avg Revenue beat(12)-3.34%
Revenue beat(16)1
Avg Revenue beat(16)-3.08%
PT rev (1m)0%
PT rev (3m)2.94%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-1.64%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 22.47
Fwd PE 14.79
P/S 1.18
P/FCF 14.75
P/OCF 13.91
P/B 6.4
P/tB 29
EV/EBITDA 18.75
EPS(TTM)0.32
EY4.45%
EPS(NY)0.49
Fwd EY6.76%
FCF(TTM)0.49
FCFY6.78%
OCF(TTM)0.52
OCFY7.19%
SpS6.08
BVpS1.12
TBVpS0.25
PEG (NY)N/A
PEG (5Y)2.08
Profitability
Industry RankSector Rank
ROA 3.83%
ROE 13.49%
ROCE 8.33%
ROIC 6.42%
ROICexc 9.94%
ROICexgc 16.75%
OM 4.57%
PM (TTM) 2.49%
GM 80.2%
FCFM 8.02%
ROA(3y)11.51%
ROA(5y)16.14%
ROE(3y)23.28%
ROE(5y)26.81%
ROIC(3y)13.7%
ROIC(5y)18.17%
ROICexc(3y)20.03%
ROICexc(5y)37.72%
ROICexgc(3y)34.31%
ROICexgc(5y)46.29%
ROCE(3y)17.8%
ROCE(5y)23.61%
ROICexcg growth 3Y-19.08%
ROICexcg growth 5Y-44.98%
ROICexc growth 3Y-31.26%
ROICexc growth 5Y-50.11%
OM growth 3Y-23.1%
OM growth 5Y-29.08%
PM growth 3Y-22.54%
PM growth 5Y-29.4%
GM growth 3Y0.1%
GM growth 5Y-0.45%
F-Score6
Asset Turnover1.54
Health
Industry RankSector Rank
Debt/Equity 1.66
Debt/FCF 3.83
Debt/EBITDA 4.43
Cap/Depr 20.71%
Cap/Sales 0.48%
Interest Coverage 6.78
Cash Conversion 123.03%
Profit Quality 321.81%
Current Ratio 3.94
Quick Ratio 3.15
Altman-Z 4.18
F-Score6
WACC8.35%
ROIC/WACC0.77
Cap/Depr(3y)22.88%
Cap/Depr(5y)30.44%
Cap/Sales(3y)0.46%
Cap/Sales(5y)0.6%
Profit Quality(3y)95.18%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-25.58%
EPS 3Y21.48%
EPS 5Y10.79%
EPS Q2Q%-30%
EPS Next Y-53.64%
EPS Next 2Y5.12%
EPS Next 3Y26.34%
EPS Next 5Y30.78%
Revenue 1Y (TTM)4.21%
Revenue growth 3Y32.02%
Revenue growth 5Y42.02%
Sales Q2Q%0.1%
Revenue Next Year4.43%
Revenue Next 2Y11.84%
Revenue Next 3Y14.78%
Revenue Next 5Y16.39%
EBIT growth 1Y-52.39%
EBIT growth 3Y1.53%
EBIT growth 5Y0.72%
EBIT Next Year-9.17%
EBIT Next 3Y38.13%
EBIT Next 5Y34.56%
FCF growth 1Y-3.04%
FCF growth 3YN/A
FCF growth 5Y14.72%
OCF growth 1Y-0.41%
OCF growth 3Y178.73%
OCF growth 5Y13.54%